| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 E3 ubiquitin ligases as cancer targets and biomarkers Sun YNeoplasia  2006[Aug]; 8 (8): 645-54E3 ubiquitin ligases are a large family of proteins that are engaged in the  regulation of the turnover and activity of many target proteins. Together with  ubiquitin-activating enzyme E1 and ubiquitin-conjugating enzyme E2, E3 ubiquitin  ligases catalyze the ubiquitination of a variety of biologically significant  protein substrates for targeted degradation through the 26S proteasome, as well  as for nonproteolytic regulation of their functions or subcellular localizations.  E3 ubiquitin ligases, therefore, play an essential role in the regulation of many  biologic processes. Increasing amounts of evidence strongly suggest that the  abnormal regulation of some E3 ligases is involved in cancer development.  Furthermore, some E3 ubiquitin ligases are frequently overexpressed in human  cancers, which correlates well with increased chemoresistance and poor clinic  prognosis. In this review, E3 ubiquitin ligases (such as murine double minute 2,  inhibitor of apoptosis protein, and Skp1-Cullin-F-box protein) will be evaluated  as potential cancer drug targets and prognostic biomarkers. Extensive study in  this field would lead to a better understanding of the molecular mechanism by  which E3 ligases regulate cellular processes and of how their deregulations  contribute to carcinogenesis. This would eventually lead to the development of a  novel class of anticancer drugs targeting specific E3 ubiquitin ligases, as well  as the development of sensitive biomarkers for cancer treatment, diagnosis, and  prognosis.|Animals[MESH]|Apoptosis[MESH]|Biomarkers, Tumor/*analysis[MESH]|Cell Transformation, Neoplastic[MESH]|Gene Expression Regulation[MESH]|Humans[MESH]|Neoplasms/diagnosis/physiopathology[MESH]|Proteins/metabolism[MESH]|Ubiquitin-Protein Ligases/*analysis/*metabolism[MESH]
 |